GHK-Cu
Also known as: Copper Peptide, GHK-Copper, Glycyl-L-Histidyl-L-Lysine:Copper(II), Copper tripeptide-1, Gly-His-Lys:copper(II), Copper peptide
GHK-Cu is the copper-bound Gly-His-Lys tripeptide, also used cosmetically as copper tripeptide-1. Its extensive cell/animal biology, mixed topical human results and small eyebrow study do not establish systemic injectable benefits.
Quick Facts
GHK, its copper complex and product contexts
GHK is glycyl-histidyl-lysine, a naturally occurring tripeptide identified in human serum in the 1970s. GHK-Cu is its copper(II) complex; copper tripeptide-1 is the cosmetic ingredient name. The copper-free peptide, copper complex, topical serum and injectable preparation are not interchangeable exposures. Plasma concentrations reportedly fall from approximately 200 ng/mL at age 20 to 80 ng/mL at age 60, but an age association does not establish a replacement need. Cosmetic products target the appearance of skin; systemic wellness injections are a separate, unapproved context. For the molecular background, our introduction explains what peptides are.
Supporting references: Plasma concentrations decline with age; proposed to act as a copper complex.
Matrix, copper and gene-expression findings
Cell and animal work describes effects on collagen, elastin and glycosaminoglycan production, matrix-metalloproteinase regulation, copper delivery, antioxidant signaling, inflammation and new-vessel formation. Fibroblast collagen synthesis was stimulated at roughly 10⁻¹²–10⁻¹¹ M, peaking near 10⁻⁹ M independently of cell-count changes. Rat wound-chamber work found concentration-related collagen increases, increased type I/III collagen mRNA without increased TGF-beta mRNA, and approximately twice the stimulation of collagen versus non-collagen protein synthesis.
Connectivity Map analyses reported changes of at least 50% in 31.2% of examined human genes. A 2012 review of PC3/MCF7 data at 1 μM described 268 upregulated and 167 suppressed genes; among genes changed at least 50%, 59% increased and 41% decreased. Across 13,424 genes, 14 antioxidant genes were stimulated. These experimental observations do not establish whole-body age reversal. A separate 2012 lung-tissue/fibroblast study examined an emphysema-related signature, not systemic treatment of aging in people.
Supporting references: gene-expression analyses; gene programs; stimulated collagen synthesis; raised collagen content in a concentration-dependent way; reported 268 genes with increased expression.
Human topical findings are mixed
Manufacturer-associated cosmetic work reports favorable appearance findings. Three 12-week topical studies, described as placebo-controlled and involving 41–71 women each, reported changes in laxity, clarity, firmness and fine lines. A thigh-biopsy report described increased collagen production in 70% with GHK-Cu versus 50% with vitamin C cream and 40% with retinoic acid. These are formulation- and study-specific findings, not proof of a general injection effect.
| Study context | Finding and boundary |
|---|---|
| 1994 diabetic-ulcer study | A named topical gel plus standardized wound care produced median plantar-ulcer area closure of 98.5% versus 60.8% with vehicle. These are area-closure percentages, not proportions of patients cured. |
| 1992 venous-ulcer study | No cream-versus-placebo difference among 86 evaluable completers. |
| Post-CO2-laser skincare | Independent randomized study with 13 completers found no statistically significant objective redness, wrinkle or skin-quality advantage, although patient-rated overall skin quality favored GHK-Cu (p=0.04). |
Supporting references: studies; articles; randomized trial of 13 patients; thigh-skin biopsy study.
Injected and wound-model findings
Injectable systemic evidence remains preclinical rather than a robust controlled human program. In rats after knee-ligament reconstruction, weekly joint injections for four weeks reduced the knee-laxity difference versus saline at six weeks (p=0.009), but the difference was not significant at 12 weeks. In mice with lipopolysaccharide-induced acute lung injury, GHK-Cu reduced TNF-alpha and IL-6 with NF-κB p65/p38 MAPK suppression.
A separate experiment applied 2% Iamin GHK-Cu gel to ischemic full-thickness wounds in 24 Sprague–Dawley rats. Day-13 area reduction was 64.5%, versus 45.6% with vehicle and 28.2% untreated. TNF-alpha, MMP-2 and MMP-9 were lower; rat tissue also showed increased superoxide dismutase and catalase. Local animal inflammatory findings do not establish clinical treatment of elevated CRP or systemic inflammatory disease.
Supporting references: Weekly joint injections for 4 weeks; lowered TNF-alpha and IL-6 through NF-κB p65 and p38 MAPK suppression; Injected GHK-Cu transiently improved ligament-graft healing; GHK-Cu reduced acute lung injury; 64.5% wound area reduction at day 13; raised superoxide dismutase and catalase levels.
Hair and eyebrow evidence, with peptide identity retained
A small 2026 proceedings report studied 18 adults using 2% GHK-Cu serum on one eyebrow and vehicle on the other for 12 weeks. Sampled week-12 hair counts were 30.50 versus 28.67, with favorable diameter/photographic findings and no reported adverse reactions. It is preliminary eyebrow evidence, not proof of scalp-alopecia treatment, injection efficacy or long-term safety.
Other cited hair experiments used different materials: copper-binding PC1031 enlarged follicles in fuzzy rats similarly to topical minoxidil; AHK-Cu, a different tripeptide, promoted elongation in human follicles outside the body, with dermal-papilla proliferation and reduced cell death; an earlier mouse study examined peptide-copper complexes. These should not all be called clinical trials of GHK-Cu.
Supporting references: enlarged hair follicles similarly to topical minoxidil; stimulated elongation of human hair follicles; mouse study.
Comparison with retinoids
Retinoids act through nuclear retinoic-acid receptors, whereas GHK-Cu’s hypotheses involve copper delivery and broader signaling. In a 48-week randomized study of 99 people with photoaging, 0.1% and 0.025% tretinoin gave similar improvement but the higher concentration caused more erythema and scaling. Retinoids have a larger evidence base and an approved prescription formulation, tretinoin. GHK-Cu cosmetic studies used different products, populations and methods, so those studies do not establish comparative equivalence or superiority.
Supporting references: act through nuclear retinoic acid receptors; erythema and scaling were significantly greater; FDA-approved prescription form, tretinoin.
Topical cosmetics, compounding and injections
FDA does not preapprove most cosmetic ingredients. Copper tripeptide-1 products may describe the appearance or feel of skin; medical structure/function claims can move a product into drug regulation. Cosmetic use is not an approved-drug indication.
GHK-Cu systemic/injectable wellness use is not FDA-approved. The retained May 14, 2026 FDA document placed GHK-Cu except injectable routes in Category 1 after nomination clarification. This route-specific compounding development is not finished-drug approval or permission for injections. Advisory recommendations, interim policies and final rulemaking remain different milestones.
Finished formulations and safety
Topical serums, creams, post-procedure skincare and some scalp products aim for firmer-looking, smoother skin and less visible fine lines. Tolerability is generally favorable in small topical work, but high copper concentrations can irritate and any new product can provoke sensitivity. Strong acids, high-strength vitamin C or certain exfoliants may destabilize the ingredient; this is chiefly a formulation issue rather than proof of a dangerous interaction. Patch testing can identify intolerance.
No universal topical concentration, injectable dose, meal rule, cycle or combination protocol is established. Cosmetic serums are not injectable products, and microneedle-assisted delivery differs from ordinary topical use. Natural copper binding does not establish pregnancy safety, rare-event rates or year-long injection safety. No general copper-monitoring or anti-aging injection protocol is validated by these studies.
References and further reading
This reference draws on Superpower reference 1, Superpower reference 2 and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1155/2015/648108Human topical findings are mixedCited in: Human topical findings are mixed
- 10.3390/brainsci7020020Matrix, copper and gene-expression findingsCited in: Matrix, copper and gene-expression findings
- 10.1163/156856208784909435Human topical findings are mixedCited in: Human topical findings are mixed
- 10.1001/archfaci.8.4.252Human topical findings are mixedCited in: Human topical findings are mixed
- 10.1002/jor.22831Injected and wound-model findingsCited in: Injected and wound-model findings
- 10.18632/oncotarget.11168Injected and wound-model findingsCited in: Injected and wound-model findings
- pmc.ncbi.nlm.nih.govGHK, its copper complex and product contextsCited in: GHK, its copper complex and product contexts
- pubmed.ncbi.nlm.nih.govGHK, its copper complex and product contextsCited in: GHK, its copper complex and product contexts
- pubmed.ncbi.nlm.nih.govMatrix, copper and gene-expression findingsCited in: Matrix, copper and gene-expression findings
- pubmed.ncbi.nlm.nih.govMatrix, copper and gene-expression findingsCited in: Matrix, copper and gene-expression findings
- pmc.ncbi.nlm.nih.govHuman topical findings are mixedCited in: Human topical findings are mixed
- pubmed.ncbi.nlm.nih.govInjected and wound-model findingsCited in: Injected and wound-model findings
- pubmed.ncbi.nlm.nih.govHair and eyebrow evidence, with peptide identity retainedCited in: Hair and eyebrow evidence, with peptide identity retained
- pubmed.ncbi.nlm.nih.govHair and eyebrow evidence, with peptide identity retainedCited in: Hair and eyebrow evidence, with peptide identity retained
- pubmed.ncbi.nlm.nih.govHair and eyebrow evidence, with peptide identity retainedCited in: Hair and eyebrow evidence, with peptide identity retained
- pubmed.ncbi.nlm.nih.govComparison with retinoidsCited in: Comparison with retinoids
- pubmed.ncbi.nlm.nih.govComparison with retinoidsCited in: Comparison with retinoids
- accessdata.fda.govComparison with retinoidsCited in: Comparison with retinoids
- pmc.ncbi.nlm.nih.govMatrix, copper and gene-expression findingsCited in: Matrix, copper and gene-expression findings
- pmc.ncbi.nlm.nih.govInjected and wound-model findingsCited in: Injected and wound-model findings
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- so09.tci-thaijo.org — additional reading
- pubmed.ncbi.nlm.nih.gov — additional reading
- www.fda.gov — additional reading
Frequently Asked Questions About GHK-Cu
GHK-Cu has collagen-related experiments and formulation-specific topical human findings. Results vary by study, and they do not establish that every serum improves wrinkles, scars or wounds.
GHK is a naturally occurring serum tripeptide that can bind copper. That does not establish a deficiency requiring replacement or the safety of every added formulation and route.
A small 2026 controlled eyebrow study reported favorable findings. That is preliminary eyebrow evidence, not established scalp hair-loss treatment; the often-cited 2007 follicle study tested AHK-Cu, a different copper peptide.
The 12-week eyebrow study and other topical trials describe particular observation periods, not a universal time to benefit. No general injectable skin or anti-aging timeline is established here.
It is the copper(II)-bound form of Gly-His-Lys. Copper tripeptide-1 is its cosmetic name; plain GHK and related AHK-Cu are distinct identities. Natural serum occurrence does not establish a deficiency requiring treatment.
Cell and rat studies support collagen/matrix activity, with effects from about 10⁻¹²–10⁻¹¹ M and a peak around 10⁻⁹ M in fibroblast work. Human cosmetic and biopsy findings are small and formulation-specific rather than proof of systemic tissue repair.
Animal wound models are favorable, and one diabetic-ulcer gel study reported 98.5% versus 60.8% median area closure alongside standardized care. A venous-ulcer study and objective post-laser outcomes were neutral. These cannot become a guarantee for any serum or injection.
The small 2026 eyebrow report was favorable over 12 weeks, but does not establish scalp treatment. The frequently cited human-follicle experiment used AHK-Cu outside the body, while PC1031 and other copper complexes were tested in animals.
The mechanisms and study designs differ. Tretinoin has a larger clinical base, with irritation a known tradeoff; 0.1% produced more erythema/scaling than 0.025% in a 99-person, 48-week study despite similar improvement. No cross-study comparison establishes GHK-Cu equivalence.
Cell and animal findings include NF-κB-related signaling, lower TNF-alpha/IL-6 in mouse lung injury, lower TNF-alpha in rat wounds and antioxidant-gene/enzyme changes. They do not establish a clinical systemic anti-inflammatory treatment.
No. Topical cosmetic or wound findings have different exposures and purposes. Robust controlled human efficacy and safety for injectable skin, hair or general tissue-repair wellness use are not established.
Related Peptides
Continue exploring GHK-Cu
- Copper Peptides for Hair Growth: GHK-Cu Hair Restoration GuideGuide
- Copper Peptides for Skin: GHK-Cu Skincare GuideGuide
- GHK-Cu Before and After: Real Results & What to Expect [2026]Guide
- GHK-Cu Benefits: Complete Guide to Copper Peptide [2026]Guide
- GHK-Cu Dosage Guide: Injection Protocol & Dosage Chart [2026]Guide
- GHK-Cu for Hair Growth: Research, Dosage & Results [2026]Guide
- GHK-Cu Peptide: Benefits, Forms, Dosing & ResearchGuide
- GHK-Cu Serum Guide: Best Copper Peptide Serums for Skin & Hair (2026)Guide
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.